Impact of COVID-19 vaccination on hospitalization in a third-level hospital
e202202022
Keywords:
COVID-19, Hospitalization, Vaccination, Severity, SARS-CoV-2 infectionAbstract
Background: This study presents information on the evolution of severe cases of SARS-CoV-2 infection that required hospitalization since the beginning of vaccination in Spain. The objective was to know the impact of vaccination against Covid-19 on the hospitalization of patients with SARS-CoV-2 infection, hospital mortality and readmissions for this cause, and to describe the characteristics of vaccinated patients who required admission.
Methods: A retrospective, observational epidemiological study was conducted of all patients admitted with SARS-CoV-2 infection confirmed by a diagnostic test for active infection (PDIA) in a tertiary hospital, from January 2021 to June 2021. The incidence of admissions was calculated based on the vaccination status of the patients and age groups at different times according to the progress of the strategy of vaccination Covid-19.
Results: Between December 27, 2020 and June 30, 2021, 1,308 patients with positive PDIA were admitted to the University Hospital of Salamanca, of which 1,167 (89.2%) were not vaccinated, 129 (9.9%) had received one dose of vaccine and 12 (0.9%) were fully vaccinated. Of the latter, none were admitted to the ICU and 2 died.
Conclusions: Vaccination against Covid-19 has contributed to the decrease in hospitalizations, since February 2021, of older and institutionalized people. Fully vaccinated people have a lower risk of admission to the ICU and death. These data, together with the information available on recent cases of new SARS-CoV-2 infections in unvaccinated young people, are in favor of achieving high vaccination coverage of the entire population in the shortest possible time.
Downloads
References
Cavaleri M, Enzmann H, Straus S, Cooke E. The European Medicines Agency’s EU conditional marketing authorisations for COVID-19 vaccines. Lancet Lond Engl. 30 de enero de 2021;397(10272):355-357.
Glanville D. COVID-19 vaccines: authorised [Internet]. European Medicines Agency. 2021 [citado 15 de septiembre de 2021]. Disponible en: https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/vaccines-covid-19/covid-19-vaccines-authorised
Estrategia de vacunación frente a COVID-19 en España. Actualización 8. Grupo de Trabajo Técnico de Vacunación COVID-19, de la Ponencia de Programa y Registro de Vacunaciones. 22 junio de 2021 [Internet]. [citado 15 de septiembre de 2021]. Disponible en: https://www.mscbs.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/covid19/docs/COVID-19_Actualizacion8_EstrategiaVacunacion.pdf
Mazagatos C, Monge S, Olmedo C, Vega L, Gallego P, Martín-Merino E et al. Effectiveness of mRNA COVID-19 vaccines in preventing SARS-CoV-2 infections and COVID-19 hospitalisations and deaths in elderly long-term care facility residents, Spain, weeks 53 2020 to 13 2021. Eurosurveillance. 17 de junio de 2021;26(24):2100452.
Análisis de la efectividad y el impacto de la vacunación frente a COVID-19 en residentes de centros de mayores en España. Grupo de Trabajo de Efectividad Vacunación COVID-19. 25 abril de 2021 [Internet]. [citado 15 de septiembre de 2021]. Disponible en: https://www.mscbs.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/covid19/docs/Efectividad_Residentes_Centros_Mayores_Informe.pdf
Decreased SARS-CoV-2 viral load following vaccination | medRxiv [Internet]. [citado 15 de septiembre de 2021]. Disponible en: https://www.medrxiv.org/content/10.1101/2021.02.06.21251283v1
Turner JS, Kim W, Kalaidina E, Goss CW, Rauseo AM, Schmitz AJ et al. SARS-CoV-2 infection induces long-
lived bone marrow plasma cells in humans. Nature. julio de 2021;595(7867):421-425.
Gestión integral de la vacunación COVID-19. Informe de actividad. 30 junio de 2021 [Internet]. [citado 15 de septiembre de 2021]. Disponible en: https://www.mscbs.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov/documentos/Informe_GIV_comunicacion_20210630.pdf
Martínez-Baz I, Miqueleiz A, Casado I, Navascués A, Trobajo-Sanmartín C, Burgui C et al. Effectiveness of COVID-19 vaccines in preventing SARS-CoV-2 infection and hospitalisation, Navarre, Spain, January to April 2021. Eurosurveillance. 27 de mayo de 2021;26(21):2100438.
Haas EJ, Angulo FJ, McLaughlin JM, Anis E, Singer SR, Khan F et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet Lond Engl. 15 de mayo de 2021;397(10287):1819-1829.
Tenforde MW, Olson SM, Self WH, Talbot HK, Lindsell CJ, Steingrub JS et al. Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Among Hospitalized Adults Aged ≥65 Years - United States, January-March 2021. MMWR Morb Mortal Wkly Rep. 7 de mayo de 2021;70(18):674-679.
Mallapaty S. Vaccines are curbing COVID: Data from Israel show drop in infections. Nature. febrero de 2021;590(7845):197.
Bertsimas D, Lukin G, Mingardi L, Nohadani O, Orfanoudaki A, Stellato B et al. COVID-19 mortality risk assessment: An international multi-center study. PloS One. 2020;15(12):e0243262.
Weiss P, Murdoch DR. Clinical course and mortality risk of severe COVID-19. Lancet Lond Engl. 28 de marzo de 2020;395(10229):1014-1015.
Robust estimation of diagnostic rate and real incidence of COVID-19 for European policymakers [Internet]. [citado 15 de septiembre de 2021]. Disponible en: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0243701
Català M, Marchena M, Conesa D, Palacios P, Urdiales T, Alonso S et al. Monitoring and Analysis of COVID-19 Pandemic: The Need for an Empirical Approach. Front Public Health. 2021;9:806.
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2022 Ana Mª Haro Pérez, Vega E. Benito López, Mar Jiménez Rodríguez, Irene Ai-Ling García Yu, Saray Martín Monteagudo
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Usted es libre de:
Compartir — copiar y redistribuir el material en cualquier medio o formato.
La licenciante no puede revocar estas libertades en tanto usted siga los términos de la licencia.
Bajo los siguientes términos:
Atribución — Usted debe dar crédito de manera adecuada , brindar un enlace a la licencia, e indicar si se han realizado cambios. Puede hacerlo en cualquier forma razonable, pero no de forma tal que sugiera que usted o su uso tienen el apoyo de la licenciante.
NoComercial — Usted no puede hacer uso del material con propósitos comerciales.
SinDerivadas — Si remezcla, transforma o crea a partir del material, no podrá distribuir el material modificado.
No hay restricciones adicionales — No puede aplicar términos legales ni medidas tecnológicas que restrinjan legalmente a otras a hacer cualquier uso permitido por la licencia.
Avisos:
No tiene que cumplir con la licencia para elementos del material en el dominio público o cuando su uso esté permitido por una excepción o limitación aplicable.
No se dan garantías. La licencia podría no darle todos los permisos que necesita para el uso que tenga previsto. Por ejemplo, otros derechos como publicidad, privacidad, o derechos morales pueden limitar la forma en que utilice el material.
